Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. (OTCMKTS:FSNUY) was the target of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 8,663 shares, a decline of 82.5% from the May 14th total of 49,381 shares. Based on an average daily volume of 403,780 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Fresenius SE & Co. Price Performance

Shares of FSNUY opened at $10.83 on Wednesday. The firm has a market capitalization of $24.40 billion, a PE ratio of 14.44 and a beta of 0.64. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.27 and a quick ratio of 0.98. Fresenius SE & Co. has a 1-year low of $10.33 and a 1-year high of $33.93. The company’s fifty day moving average price is $11.93 and its 200-day moving average price is $13.38.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.75 billion for the quarter, compared to analysts’ expectations of $6.79 billion. Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.09%. On average, equities research analysts predict that Fresenius SE & Co. will post 1.05 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a report on Monday, April 20th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.